{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:57:50Z","timestamp":1759010270505,"version":"3.41.2"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2017YFC0112000"],"award-info":[{"award-number":["2017YFC0112000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>The objectives were to investigate the safety and efficacy of thermal ablation as an alternative to liver transplantation for hepatocellular carcinoma patients with clinically significant portal hypertension (CSPH).<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>From July 2016 to September 2019, hepatocellular carcinoma patients with CSPH treated by liver transplantation (N=37) or thermal ablation (N=114) were enrolled. Cumulative intrahepatic recurrence, overall survival and major complications were compared by propensity score matching.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the two matched groups, the 1-, 2-, and 3-year intrahepatic recurrence rates for the ablation group (22.3%, 50.0%, and 50.0%, respectively) were significantly higher than those for the transplantation group (4.5%, 4.5%, and 4.5%, respectively) (P=0.016). The 1-, 2-, and 3-year overall survival rates were comparable between the two groups [96.1%, 88.7%, and 88.7%, respectively (ablation group) <jats:italic>vs<\/jats:italic>. 84.6%, 76.2%, and 76.2%, respectively (transplantation group)] (P=0.07). The major complication rate for the ablation group [4.8% (3\/62)] was significantly lower than that for the transplantation group [36.0% (9\/25)] (P&amp;lt;0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Thermal ablation is a safe and effective alternative for hepatocellular carcinoma patients with CSPH.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1103347","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T12:16:22Z","timestamp":1687781782000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Thermal ablation as an alternative to liver transplantation for hepatocellular carcinoma with clinically significant portal hypertension: propensity score matching study"],"prefix":"10.3389","volume":"13","author":[{"given":"Yinglin","family":"Long","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhou","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingjing","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erjiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuqi","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianxiong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binsheng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/jhbp.124","article-title":"Influence of clinically significant portal hypertension on surgical outcomes and survival following hepatectomy for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"21","author":"Choi","year":"2014","journal-title":"J Hepatobil Pancreat Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28824","article-title":"Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: the \u201cAnticipate\u201d study","volume":"64","author":"Abraldes","year":"2016","journal-title":"Hepatology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1053\/j.gastro.2012.10.001","article-title":"Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis","volume":"144","author":"Berzigotti","year":"2013","journal-title":"Gastroenterology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3233\/CH-168118","article-title":"Vascular complications in liver transplantation : beneficial role of contrast-enhanced ultrasound (CEUS) in the postoperative phase","volume":"64","author":"R\u00fcbenthaler","year":"2016","journal-title":"Clin Hemorheol Microcirc"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2009.03.002","article-title":"Comprehensive ultrasound assessment of complications post-liver transplantation","volume":"74","author":"Brien","year":"2010","journal-title":"Eur J Radiol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin Liver Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.jhep.2012.05.007","article-title":"A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma","volume":"57","author":"Feng","year":"2012","journal-title":"J Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-016-4604-z","article-title":"The impact of clinically significant portal hypertension on the prognosis of patients with hepatocellular carcinoma after radiofrequency ablation: a propensity score matching analysis","volume":"27","author":"Fang","year":"2017","journal-title":"Eur Radiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2017.1390787","article-title":"Thermal ablation of hepatocellular carcinoma in patients with abnormal coagulation function","volume":"34","author":"Huang","year":"2018","journal-title":"Int J Hyperth"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20892","article-title":"Percutaneous radiofrequency ablation for hepatocellular carcinoma an analysis of 1000 cases","volume":"103","author":"Tateishi","year":"2005","journal-title":"Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.15141483","article-title":"Small hepatocellular Carcinoma : radiofrequency ablation versus nonanatomic resection-propensity score analyses of long-term outcomes","volume":"275","author":"Kang","year":"2015","journal-title":"Radiology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000129672.51886.44","article-title":"Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver","volume":"240","author":"Vivarelli","year":"2004","journal-title":"Ann Surg"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000001178","article-title":"Surgical resection versus radiofrequency ablation for single hepatocellular carcinoma \u2264 2 cm in a propensity score model","volume":"263","author":"Liu","year":"2016","journal-title":"Ann Surg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2016.193","article-title":"Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches","volume":"14","author":"Sapisochin","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000001966","article-title":"Recurrence after liver transplantation for hepatocellular carcinoma: a new MORAL to the story","volume":"265","author":"Halazun","year":"2017","journal-title":"Ann Surg"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3181efc656","article-title":"A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria","volume":"252","author":"Huang","year":"2010","journal-title":"Ann Surg"},{"key":"B20","doi-asserted-by":"publisher","first-page":"16018","DOI":"10.1038\/nrdp.2016.18","article-title":"Hepatocellular carcinoma","volume":"2","author":"Llovet","year":"2016","journal-title":"Nat Rev Dis Prim"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23965","article-title":"Repeated radiofrequency ablation for management of patients with cirrhosis with small hepatocellular carcinomas: a long-term cohort study","volume":"53","author":"Rossi","year":"2011","journal-title":"Hepatology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/jso.21415","article-title":"Liver transplantation versus liver resection for the treatment of hepatocellular carcinoma","volume":"101","author":"Lee","year":"2010","journal-title":"J Surg Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000225255.01668.65","article-title":"Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long-term survival","volume":"245","author":"Poon","year":"2007","journal-title":"Ann Surg"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S1499-3872(14)60037-0","article-title":"Liver transplantation versus liver resection for hepatocellular carcinoma: a meta-analysis","volume":"13","author":"Xu","year":"2014","journal-title":"Hepatobil Pancreat Dis Int"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.10.006","article-title":"EASL clinical practice guidelines: liver transplantation","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i18.5363","article-title":"Liver transplantation: fifty years of experience","volume":"20","author":"Song","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2011.00817.x","article-title":"Percutaneous radiofrequency ablation for liver tumors: is it safer and more effective in low-risk areas than in high-risk areas","volume":"41","author":"Tang","year":"2011","journal-title":"Hepatol Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2012.01025.x","article-title":"Complications of radiofrequency ablation for hepatocellular carcinoma in a multicenter study: an analysis of 16346 treated nodules in 13283 patients","volume":"42","author":"Koda","year":"2012","journal-title":"Hepatol Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1586\/egh.12.83","article-title":"Assessing portal hypertension in liver diseases","volume":"7","author":"Berzigotti","year":"2013","journal-title":"Expert Rev Gastroenterol Hepatol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1103347\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T09:56:33Z","timestamp":1688118993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1103347\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,26]]},"references-count":29,"alternative-id":["10.3389\/fonc.2023.1103347"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1103347","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2023,6,26]]},"article-number":"1103347"}}